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Abstract 
Although primary localised tumours of renal cell carcinoma (RCC) can be treated relatively 
successfully with surgery, metastatic RCC has poor prognosis because of late diagnosis and 
resistance to therapies. In the present study, we were interested in profiling the protein 
expression of “inhibitor of caspase-activated DNase” (ICAD), an apoptosis inhibitor, in 
kidney cancer and its paired normal kidney. Immunohistochemistry with automated batch 
staining and morphometry using digital pathology were used to compare ICAD in 121 RCC 
specimens with their paired normal kidney tissue. Tissue microarray of formalin-fixed, 
paraffin-embedded archival tissue was used. Intensity and localisation of ICAD were 
compared between normal and cancer samples, and against grading within the cancers. 
The results demonstrated that, in this cohort, ICAD was highly expressed in the proximal 
tubular epithelium of normal kidney, and significantly decreased in clear cell RCC tissue (p 
< 0.05) as well as other subtypes of RCC (p < 0.01) compared with normal kidney. There 
was a tendency towards nuclear localisation of ICAD in clear cell RCC, but not in other 
subtypes of RCC. No significant association was found between ICAD intensity and grade of 
RCC. In summary, down-regulation of ICAD occurs in RCC. ICAD normally inhibits DNA 
fragmentation and apoptosis; thus, its down-regulation was unexpected in a cancer known 
for its resistance to apoptosis. However, these RCC samples were from primary, not 
metastatic, RCC sites, and down-regulated ICAD may be part of a progressive pathway that 
promotes RCC metastasis. 
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Introduction 
Renal neoplasms account for 
approximately 3% of the total human 
cancers. Renal cell carcinomas (RCCs), the 
major proportion of renal neoplasms, are 
the tenth leading cause of cancer mortality 
in Western industrialised countries, 
including Australia (1–3). RCC represents 
on average 90% of the renal neoplasms in 
adults of both sexes worldwide (3). 
Although surgery is a successful curative 
treatment for localised RCC, metastasis is 
common and these metastases are 
resistant to cancer therapies. Improving 
therapy-associated kidney cancer 
regression would be of great benefit to 
patients. Increased knowledge of the 
underlying molecular characteristics of 
RCC will result in the identification of 
molecular pathways involved in tumour 
growth and metastasis, and resistance to 
therapies, and expedite development of 
targeted therapies, and may also identify 
useful markers of RCC development and 
progression. 
The failure in initiation of apoptosis is a 
hallmark of treatment-resistant tumours 
(4, 5). However, understanding the 
intricacies of how cells fail in the apoptotic 
process is complex and very tissue specific. 
In most instances, induction of apoptosis 
requires DNA fragmentation. The enzyme 
responsible for apoptotic DNA 
fragmentation is caspase-activated DNase 
(CAD). CAD is normally inhibited by the 
inhibitor of CAD (ICAD). During apoptosis, 
the effector caspase, caspase-3, cleaves 
ICAD, causing CAD to become activated 
and degradation of nuclear DNA into 
nucleosomal units to occur (6–8). 
CAD and ICAD are members of the cell 
death–inducing DFF-45 effector (CIDE) 
protein family (9). Members CIDE-A and 
CIDE-B promote cell death and DNA 
fragmentation. They are inhibited by ICAD 
and activated by CAD. The CIDEs, ICAD 
and CAD have not yet been widely studied 
in cancer in general, let alone in RCC. 
CIDE-B has shown some prospect as a 
biomarker for cancers. For example, CIDE-
B was found to be up-regulated in a 
proteomic study of cervical cancer after 
treatment with 5-fluorouracil, and it was 
also found to interact with chronic 
hepatitis C virus infection to induce liver 
cancer (10). Hara et al. (11) found, using a 
cell culture model of RCC, that when ICAD 
was over-expressed in tumour cells, it 
rendered them highly-resistant to therapy-
induced apoptosis, an outcome that could 
possibly result in enhanced tumour 
progression in an in vivo situation (11). In a 
more recent cell culture study, multiple 
RCCs were treated with chemotherapy 
and/or radiotherapy, and RNA microarray 
technology was used to analyse expression 
of apoptosis-related genes in resistance to 
cancer therapy (12). In this investigation, 
one of the novel genes, not previously 
characterised in RCC apoptosis, but 
showing a multi-fold increase in expression 
in RNA microarray, was ICAD. ICAD could 
contribute to increased inhibition of 
caspase-dependent cell death in RCC when 
they are treated with chemotherapeutics. 
However, it is also known that cells that 
lack ICAD, or express a caspase-resistant 
mutant of ICAD, do not show DNA 
fragmentation during apoptosis, but may 
die via other cell death pathways (13, 14). 
There have been no published studies of 
ICAD expression in human patient kidney 
cancer samples. The aim of this paper was 
to use a set of archival tissue blocks of RCC, 
characterised and diagnosed by the WHO 
classification system of 2004 (15) plus their 
paired normal tissue, to prepare tissue 
microarrays (TMAs) and to evaluate and 
profile ICAD using immunohistochemistry 
(IHC) and morphometry. In this 
investigation, TMAs were designed to 
include the main RCC subtypes (clear cell, 
collecting duct, papillary, chromophobe) 
and unclassified RCC. Histology grade using 
a grading system based on Fuhrman’s 
classification (Table 1) (16) was compared 
amongst RCC samples, and intensity of 
ICAD expression in the RCC subtypes was 
compared amongst RCC subtypes and with 
normal kidney. We were investigating 
whether profiling the protein expression of 
ICAD in TMAs could lead to a better 
understanding of RCC development. 
Methods 
Ethics approvals 
Ethics approval was obtained from the 
University of Queensland Human Research 
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Table 1. Fuhrman histological grade for RCC (16) 
Fuhrman grade Definition 
1 Tumour cells with small (~10 µm), round, uniform nuclei without 
nucleoli 
2 Tumour cells with larger nuclei (~15 µm); irregularities in nuclei 
and nucleoli when examined under high power (400) 
3 Tumour cells with even larger nuclei (~20 µm); obvious irregular 
outline and prominent larger nucleoli at low power (100) 
4 Tumour cells with bizarre, multilobed nuclei and heavy clumps of 
chromatin 
 
 
Ethics Committee and the Princess 
Alexandra Hospital (PAH) Human Research 
Ethics Committee for these analyses (PAH 
HREC Approval 2006/189 and University 
of Queensland HREC Approval 
2007000023). The original tissue blocks 
had been archived for research purposes 
with patient consent. 
General TMA protocol 
Tumour biopsies were retrieved from 
selected regions of 121 archival RCC 
tumour tissue blocks of various subtypes 
(clear cell RCC, n = 95; papillary RCC, n = 
11; chromophobe RCC, n = 6; collecting 
duct RCC, n = 4; and unclassified RCC,  
n = 5) from the PAH tumour tissue bank. 
The final number of biopsies used was 95. 
We acknowledge pathologist Dr J Perry-
Keene for her work in re-classifying the 
archival RCC samples according to the 
2004 WHO classification system (15). The 
paired normal kidney tissue was also used 
for each patient. The selected samples 
were precisely arrayed in new paraffin 
blocks to investigate and identify novel 
genes and genetic changes of potential 
importance in RCC. To carry out the TMA 
preparation, histology tissue blocks from 
the original pathology series were selected 
and a new histology section was cut so 
that there was a fresh haematoxylin and 
eosin (H&E)-stained section and a 
matching paraffin block (17). The sections 
were viewed under the microscope to 
select two representative areas of RCC or 
normal tissue from each sample block, at 
the Molecular and Clinical Pathology 
Research Laboratory, PAH. The areas of 
RCC were selected to best represent the 
RCC subtype classification. Fibrotic areas, 
glomeruli or large vessels were ignored. 
Normal tissue areas contained the 
proximal and distal tubular epithelium. 
Glomeruli and large vessels were not 
included where possible. Duplicate areas 
were selected from each section (and, 
therefore, paraffin block) to avoid any 
limitation from selection of a small core of 
tissue from a single area of one section. 
The TMA instrument used for the current 
project was a Galileo TMA CK3000 Tissue 
Microarrayer (Fantoli, Milan, Italy). The 
core punch needles used to remove the 
selected areas from the “parent” paraffin 
blocks were 0.6 mm in diameter and were 
from Beecher Instruments, Inc. (Sun 
Prairie, WI, USA). 
Immunohistochemistry 
TMA sections were cut onto Superfrost 
Plus (ThermoFisher Scientific, Vic, 
Australia) histology slides for IHC. Primary 
antibody for ICAD was from AbCam Inc, 
Cambridge MA, USA (ab15202), and 
antibody dilution was 1:200. Positive tissue 
samples (human liver, kidney and gut 
arrays) were used to verify its activity in 
human tissue, and negative controls 
without primary antibody were prepared 
for each batch stain. Non-specific binding 
of peroxidase or antibody was blocked with 
0.1% sodium azide in 0.3% hydrogen 
peroxide (H2O2) in Tris-buffered saline 
(TBS) (10 min), followed by 5% non-fat milk 
powder in TBS containing 0.05% Tween-20 
(Blotto; 20 min), then a 1:100 dilution of 
normal swine serum in 1% bovine serum 
albumin (BSA) in TBS (5 min). Antibodies 
were diluted in 1% BSA in TBS. The IHC 
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procedure was performed using a Bond-
Max automated immunostainer (Vision 
BioSystems, Mount Waverley, Australia) in 
the Histology Unit, Queensland Institute 
for Medical Research, Brisbane, Australia, 
by Histology Manager Mr Clay Winterford. 
The kit used for IHC was a Bond Polymer 
Refine Detection kit (Vision BioSystems, 
Cat #DS9800). The chromogen was 
diaminobenzidine hydrochloride (DAB). 
Sections were lightly counterstained with 
haematoxylin and then dehydrated in a 
series of ethanol, cleared in xylene and 
mounted with glass coverslips in Depex 
(Sigma-Aldrich, MO, USA). Thus, the slides 
were stained in a batch in a constant 
environment, making comparisons in 
expression patterns amongst samples as 
controlled as possible. 
Morphometry 
Digital images of the sections were 
captured using ScanScope from Aperio 
Digital Pathology systems (Leica 
Microsystems Pty Ltd, North Ryde, 
Australia). Up to three random fields of the 
same size were selected per RCC and 
paired normal kidney section, and jpg 
images were saved. A quantitative scoring 
system of overall expression, intensity and 
subcellular localisation of ICAD was 
performed. Image morphometry was 
analysed using ImagePro Plus image 
analysis software (version 4.1.29, Media 
Cybernetics, Silver Spring, MD), which 
automatically calculates the pixel area of 
DAB chromogen stained brown in each of 
the core images. In addition, a simple 
manual scoring system was used as a 
comparison with the automated 
morphometry. In this case, the analysis 
was carried out by viewing the actual 
sections using a light microscope and 
objective magnification of 40. Each core in 
each TMA was then scored manually for 
quantification of protein expression, based 
on the intensity of the staining and 
localisation of the expressed protein. 
Intensity and distribution were graded 
blinded to the subtype of RCC. For 
intensity, 1 represented no expression, and 
2, 3 and 4 represented low, moderate and 
high expression, respectively, with a 
selection towards the lower of these scores 
if there was indecision on the score. For 
localisation, protein expression in 
membrane, cytoplasm or nucleus was 
recorded. Scores for RCCs were compared 
with scores with their paired normal tissue. 
Intensity of ICAD was also compared with 
grade of each RCC. 
Statistics 
Various methods were used for statistics, 
depending on the types of analyses that 
were best for a particular set of 
comparisons. Associate Professor Zhiqiang 
Wang, Centre for Chronic Disease, 
University of Queensland, advised on some 
of the statistical analyses. Statistical 
methods employed were ANOVA with 
Bonferroni’s post hoc test, Student’s t-test, 
or Pearson 2 with a Fisher’s exact p. A 
value of p < 0.05 was considered to be 
significant in each case. 
Results 
Expression of ICAD decreases in RCC and 
localises to the nucleus in clear cell RCC 
ICAD is a downstream molecule of the 
caspases, usually inhibiting nuclear DNA 
fragmentation induced by CAD during 
apoptosis. ICAD is often located in cell 
nuclei and functions in the cytoplasm as 
an anchor for CAD or as a factor that 
enters the nucleus following caspase 
cleavage (6, 7, 14). In the current TMA 
analysis, Figure 1A demonstrates ICAD 
protein expression in normal kidney. 
Expression was strong in the cytoplasm of 
the proximal tubular epithelium of normal 
kidney, compared with distal tubular 
epithelium. The proximal tubular 
epithelium is said to be the origin of clear 
cell and papillary RCC, and distal 
tubular/collecting duct epithelium the 
origin of chromophobe and collecting duct 
RCC (3). Nuclear expression was prominent 
in the distal tubule. In Figure 1B, there is 
a region that shows an apparent transition 
to clear cell RCC (trans), and within this 
region, nuclear localisation of ICAD was 
intense, although cytoplasmic localisation 
was still seen in the proximal tubular 
epithelium. 
Figure 2 compares ICAD expression 
between normal kidney and all RCC, using 
morphometry, and examples of IHC are 
given. Because of numbers (80% of 
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samples were clear cell RCC versus only 
20% for all other RCC subtypes), we 
analysed statistics by comparing 
expression in normal kidney with clear cell 
RCC and with all other non-clear cell RCCs 
grouped together. Although expression was 
significantly lower in all RCC subtypes, it 
was lowest in non-clear cell RCC. There 
was some nuclear localisation in clear cell 
RCC, but in general no nuclear localisation 
was seen in other RCC subtypes. The 
morphometry results from the Image-Pro 
Plus (Media Cybernetics, Inc, MD, USA) 
software analyses for clear cell RCC versus 
all other RCC subtypes are plotted below 
the IHC in Figure 2. ICAD had very strong 
expression in the normal kidney, especially 
in the proximal tubular epithelium. Using 
morphometry, expression (positive pixels) 
in all RCCs was significantly lower than 
that seen in the normal tissue. 
Table 2 and Figure 3 demonstrate ICAD 
intensity scores compared between RCC 
subtypes using Pearson 2. Clear cell RCC 
was compared with all other RCC subtypes 
The Pearson 2 was 1.1437 with a p value 
of 0.564, and a Fisher’s exact p value was 
0.553. Thus, there were no significant 
differences amongst RCC subtypes using 
this analysis. Table 3 and Figure 4 
illustrate ICAD intensity scores when 
comparing Fuhrman’s histological grade 4 
with grades 1–3. The Pearson 2 was 
2.7417 with a p value of 0.254, and a 
Fisher’s exact p value was 0.327. Again, 
there were no significant differences, 
although ICAD intensity was very low in 
grade 4 RCC. 
Discussion 
While treating primary localised RCC with 
surgery is considered relatively successful, 
it is the metastases that are difficult to 
treat. The gene changes that develop in the 
primary cancers may determine the 
treatment resistance of metastases. 
Hanahan and Weinberg’s well-cited papers 
(4, 5) suggest that acquired capability of 
cancers to evade apoptosis is a key 
mechanism in progression of cancers. 
While evidence for this has developed 
principally from studies in mouse models 
and cultured cells, descriptive analysis of 
gene expression determining apoptosis in 
samples of human cancers is also a 
validated method for investigation. We 
used such a comparison in the current 
investigation. 
 
 
Figure 1. ICAD protein expression in normal kidney. In (A), expression was strong in the cytoplasm of 
the proximal tubular epithelium (PT) of normal kidney compared with distal tubular epithelium (DT) and 
glomerulus (glom). Nuclear expression is prominent in the distal tubule. In (B), there is a region that 
shows an apparent transition to clear cell RCC (trans), and within this region, nuclear localization of 
ICAD is intense, although cytoplasmic localization is still seen in the proximal tubular epithelium (PT). 
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Figure 2. ICAD protein expression and morphometry in normal kidney versus RCCs. ICAD had 
very strong expression in the normal kidney (A), especially in the proximal tubular epithelium. 
Although clear cell RCC also had relatively strong expression (B), it was significantly reduced 
compared with normal tissue (p < 0.05). Likewise, other subtypes of RCC (C and D illustrate 
chromophobe and papillary, respectively) had significantly lower expression than that seen in the 
normal tissue (p < 0.01). There was some nuclear localisation in clear cell RCC (B), but in general 
no nuclear localisation was seen in other RCC subtypes (C and D). The morphometry results from 
the Image-Pro Plus software analyses for clear cell RCC versus all other non-clear cell RCC 
subtypes are plotted below the IHC. Expression (pixels) in all RCCs was significantly lower than 
that seen in the normal tissue. There was no significant difference in expression between clear 
cell RCC and all other RCC subtypes. 
Aberrations in the normal expression of 
genes, or the abnormal induction of genes 
not associated with normal renal 
homeostasis, could underlie RCC 
development and progression. In our 
previous research, RNA isolated from RCCs 
with low and high levels of apoptosis in cell 
culture experiments was subjected to 
microarray analysis (12). Genes 
differentially expressed between the high 
and low levels of apoptosis were grouped 
into apoptotic pathways and processes. 
Resistance to apoptosis can be acquired by 
cancer cells through a variety of strategies. 
Since the apoptotic machinery is made up 
of sensors responsible for monitoring the 
extracellular and intracellular environment 
for conditions of normality or abnormality, 
their altered expression may influence 
whether a cell lives or dies. ICAD is one of 
the final targets of the caspases, effector 
molecules of the apoptotic machinery (13, 
18). Since ICAD acts to restrain CAD, its 
cleavage and inactivation by a caspase 
allows CAD to enter the nucleus and 
fragment the DNA, causing the 
characteristic DNA ladder in apoptosis. In 
our original microarray analysis of 
apoptosis in RCC, significant increases in 
RNA were found for ICAD (12), indicating 
its involvement in apoptosis resistance in 
the kidney cancer cells. Thus, TMA and 
IHC were implemented in the current study 
to investigate ICAD expression in human 
RCC samples compared with paired normal 
kidney.
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Table 2. Comparison of RCC subtypes with ICAD protein intensity (Pearson 2) 
ICAD Intensity score  
 1 2 3 4 Total 
Rest of RCCs 0 9 6 7 22 
0.00 40.91 27.27 31.82 100.00 
ccRCC only 0 30 27 16 73 
0.00 41.10 36.99 21.92 100.00 
Total 0 39 33 23 95 
0.00 41.05 34.74 24.21 100.00 
 
In the TMA analysis, ICAD was 
significantly down-regulated in RCCs 
compared with normal kidney tissue where 
it was highly expressed mainly in the 
proximal tubule. ICAD normally inhibits 
DNA fragmentation and apoptosis (19); 
thus, the down-regulation in protein 
expression was unexpected in a cancer 
known for its resistance to apoptosis. 
However, similar down-regulation was also 
seen in proliferative colon cancer cells and 
was thought to be a mechanism for colon 
cancer cells to escape the late changes of 
apoptosis, including nuclear fragmentation 
and cell disintegration (20). These results 
in colon cancer may indicate a similar role 
in RCCs. The role of ICAD is indeed 
complex. As a downstream molecule of 
caspases, ICAD participates in nuclear 
DNA fragmentation during apoptosis. 
ICAD is typically located in cell nuclei 
(21), but it also functions in the cytoplasm 
as an anchor for CAD, or as a factor that 
enters the nucleus following caspase 
cleavage in order to activate resident 
endonucleases (22, 23). Isoforms of ICAD 
might function in vivo as tissue-specific 
modulators of an overall CAD activity 
available in the nuclei of cells, by 
controlling both the specific enzymatic 
activity and the amount of CAD in the 
nuclei (24). Some alterations in nuclear 
localisation of ICAD were seen in our 
study comparing normal kidney with RCC. 
These changes may also explain, at least 
in part, the unexpected down-regulation of 
ICAD in a cancer known to be resistant to 
apoptosis.
Figure 3. Graph of the 2 results for RCC subtype with ICAD protein intensity. The ICAD 2 
analysis is shown, comparing percent of cases for clear cell RCC (ccRCC) with the other subtypes 
of RCC having differing intensity scores for protein expression (1 = no expression; 2–4 = low, 
moderate and high protein intensity). ccRCC was compared with all other RCC subtypes. The 
Pearson 2 was 1.1437 with a p value of 0.564, and a Fisher’s exact p value was 0.553. Thus, 
there were no significant differences. 
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Table 3. Comparison of RCC tumour grade with ICAD protein intensity (Pearson 2) 
ICAD Intensity score  
 1 2 3 4 Total 
Grade 1–3 0 33 31 22 86 
Grade 4 only 0 6 2 1 9 
Total 0 39 33 23 95 
 
We believe it is now possible to include ICAD 
in a provisional apoptotic signalling circuitry 
in RCC. While information is incomplete, it is 
evident that most regulatory and effector 
components of apoptosis may be redundant 
in some cells. This redundancy holds 
important implications for the development 
of novel types of antitumour therapy, since 
tumour cells that have lost proapoptotic 
components are likely to retain ones that act 
in similar pathways. New technologies may 
be able to make the most of the information 
we have presented, to determine apoptotic 
pathways that are still operative in kidney 
cancer. From this information, new drugs 
may be developed that act on intact 
components of apoptotic signalling pathways 
in tumour cells, with substantial therapeutic 
benefit. 
TMA technology should also be discussed. 
TMAs allow a molecule of interest to be 
studied within many small tissue pieces 
arrayed together into one paraffin block. The 
TMAs are prepared by relocating multiple 
tissue cores from conventional histologic 
paraffin blocks so that tissues from many 
patients can be analysed in the same slide. 
Thus, they are considered a highly efficient 
method for in situ screening of expression of 
proteins or mRNA (25–27). TMA technology 
clearly holds promise over other established 
methods for many different areas of research, 
especially in the field of cancer research (25). 
The disadvantage of this approach, however, 
is the lack a histomorphologic perspective in 
protein expression (28, 29) because tissue 
samples are small and may not be fully 
representative of a heterogeneic cancer such 
as RCC. In TMAs, IHC provides excellent 
localisation but lacks accurate quantification 
and normalisation to total cellular protein 
content (28, 30). However, as costs associated 
with assaying gene marker arrays increase, 
particularly for the testing of the efficacy of 
new drugs treatments, TMAs may well 
become a standard pre-clinical investigation 
tool (25, 31). 
Figure 4. Graph of the 2 results for ICAD grade with protein intensity. The graphical summary 
of the numbers (Y axis = counts) of RCCs with a grade of 4 (G4) and those having grades 1 to 3 
(G1–3) having a defined ICAD protein intensity (1 = no expression; 2–4 = low, moderate and high 
protein intensity). The Pearson 2 was 2.7417 with a p value of 0.254, and a Fisher’s exact p 
value was 0.327. Although there is clearly a decrease in ICAD intensity with high grade RCC, 
there was no significant difference. 
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In summary, IHC of TMAs of paired human 
RCC and normal kidney tissue showed 
positive localized protein expression of 
ICAD, with detectable variation in 
expression levels of the proteins between 
normal and cancer tissues. Decreased ICAD 
expression in RCC compared with normal 
tissue was an unexpected finding; however, 
it is also known from other cancers that 
cells that lack ICAD, or express a caspase-
resistant mutant of ICAD, may not have 
DNA fragmentation during apoptosis, or 
may die via other cell death pathways (14). 
The samples we used were also from 
patients who had received no therapy before 
resection of the cancer, and so we analysed 
endogenous ICAD expression. With a larger 
cohort for analysis, ICAD may prove useful 
as a marker of stage of progression of the 
cancer. However, it is not possible to 
hypothesise from these data whether 
treatment would have augmented 
expression above the levels of proteins 
described here. Further work is required to 
be completed with TMAs, using extended 
sampling of different subtypes and grades of 
RCC, to determine the prognostic value of 
ICAD. 
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